Bannerbild German Brest Group - Forschung

Forschungsprojekte und Publikationen der German Breast Group

Die German Breast Group erforscht Brustkrebs und setzt dafür selbst entwickelte Studienkonzepte um.

Mit zusätzlichen wissenschaftlichen Forschungsprojekten wollen wir weitere Erkenntnisse über die Krankheit gewinnen.

Neuste Forschungsnachrichten

  • 02.05.2019 GBG Research at ESMO Breast Cancer 2019

    Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.

  • 10.04.2019 Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients

    We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.

  • 01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.

  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

  • 18.01.2019 Prof. Loibl unter den meist zitierten Wissenschaftlern in 2018

    Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd